Gufic Biosciences Share Price Target 2026 Analyst Forecast Bull and Bear Case

The Gufic Biosciences share price target 2026 is Rs 430, implying approximately 20 percent upside from the current market price of Rs 360.4 (NSE: GUFICBIO). With Q4 FY26 results released in 2026 and Pharmaceutical Formulations and Biologics tailwinds in focus, the Rs 430 price objective is supported by the FY27 earnings recovery thesis.

Gufic Biosciences (NSE: GUFICBIO) is a Pharmaceutical Formulations and Biologics company trading at Rs 360.4 with a market capitalisation of Rs 3,244 crore. Analysts have set the Gufic Biosciences share price target at Rs 430 for 2026, based on FY27 earnings projections and sector re-rating potential. This article covers the complete 2026 price forecast for Gufic Biosciences including sector tailwinds, key risks, and the bull and bear scenarios.

Click Here – Get Free Investment Predictions

Gufic Biosciences Share Price Target 2026: Key Takeaways

• Gufic Biosciences share price target 2026: Rs 430 (20% upside from CMP Rs 360.4)
• Bull case: Rs 525 | Bear case: Rs 290
• Ticker: GUFICBIO | Sector: Pharmaceutical Formulations and Biologics | MCap: Rs 3,244 crore
• 52W range: Rs 250 to Rs 591 | PE: 28x
• Key catalyst: Q4 FY26 results and FY27 earnings recovery confirmation in 2026
• Key risk: FY27 earnings miss or sustained FII outflows from Indian equities

Gufic Biosciences Company Overview

Gufic Biosciences (NSE: GUFICBIO) is a Mumbai-based pharmaceutical company manufacturing specialty injectable formulations including lyophilised products, peptides, and biologic drugs for domestic hospital and regulated export markets, with FY26 revenue growing 18 percent year-on-year. At CMP Rs 360.4 against a 52 week range of Rs 250 to Rs 591, the stock is trading at a meaningful discount to its 52 week high. The trailing PE is 28x and the Rs 430 analyst target implies approximately 20 percent upside from current levels. Compared to peers in specialty pharma like Piramal Pharma and Sun Pharma, Gufic Biosciences is positioned as a potential re-rating candidate on FY27 earnings delivery.

Why Is the Gufic Biosciences Share Price Target Set at Rs 430 for 2026

FY27 Earnings Recovery and Revenue Acceleration

The Gufic Biosciences share price target of Rs 430 rests on analyst projections of 15 to 20 percent PAT growth in FY27. Q4 FY26 results released in 2026 confirming the earnings trajectory are the most direct catalyst for a re-rating. Until FY27 PAT delivery is confirmed, the Rs 430 price objective represents a base case with execution risk attached.

Structural Sector Tailwinds in Pharmaceutical Formulations and Biologics

The Pharmaceutical Formulations and Biologics sector is expanding on the back of India’s domestic demand growth, PLI scheme support, and rising corporate investment. Gufic Biosciences’s position among peers in specialty pharma like Piramal Pharma and Sun Pharma creates a structural growth runway. Sustained sector outperformance is one of the key conditions for the Rs 525 bull case to materialise, making sector monitoring essential for investors tracking this stock.

RBI Rate Cut Cycle and Lower Cost of Capital

India’s RBI rate cut cycle in 2026 is reducing borrowing costs across sectors and stimulating end market demand. For Gufic Biosciences, lower interest costs improve the EPS trajectory, narrowing the gap between current earnings and the FY27 estimates that underpin the Rs 430 analyst consensus. This rate environment is a tailwind across the Pharmaceutical Formulations and Biologics space.

Union Budget 2026-27 Capex Push and Policy Support

Budget 2026-27’s Rs 11.21 lakh crore infrastructure capex, PLI scheme continuity, and consumption incentives create a favourable policy backdrop for Gufic Biosciences’s Pharmaceutical Formulations and Biologics operations. Policy support increases the probability of Gufic Biosciences achieving its FY27 earnings targets, which in turn supports the Rs 430 price objective set by analysts for 2026.

FII Flow Normalisation After the 2026 Tariff Shock

As global macro conditions normalise through 2026, FII flows into quality Indian equities are gradually recovering. At 28x PE, Gufic Biosciences is positioned as a beneficiary of institutional reallocation into mid-cap and small-cap Indian stocks. Sustained FII inflow is a necessary condition for re-rating the stock toward the Rs 525 bull case scenario.

Gufic Biosciences Share Price Targets: Short Term, 12 Month, and Long Term

Short Term Gufic Biosciences Share Price Target

Near-term support for Gufic Biosciences is anchored near the 52 week low of Rs 250. A confirmed Q4 FY26 earnings recovery in 2026 is the trigger for an initial 10 to 15 percent re-rating. Investors eyeing a near-term entry can use the 52 week low as a key reference while awaiting the FY27 earnings confirmation that would strengthen the case for the full price objective of Rs 430.

12-Month Gufic Biosciences Share Price Target 2026

The 12-month Gufic Biosciences share price target 2026 is Rs 430, implying approximately 20 percent upside from CMP Rs 360.4. This base case assumes in-line FY27 earnings delivery and partial normalisation of FII flows. Investors can track live price movement on NSE under the ticker GUFICBIO to assess progress toward this target.

Long Term Gufic Biosciences Share Price Target: FY27 to FY28

The long term Gufic Biosciences share price target for the FY27 to FY28 period is Rs 525 in the bull case. Full earnings delivery, re-rating toward higher peer multiples among peers in specialty pharma like Piramal Pharma and Sun Pharma, and sustained institutional buying are the three conditions that need to align for the stock to reach the Rs 525 level over a 2 to 3 year horizon.

Bull Case and Bear Case Scenarios for Gufic Biosciences in 2026

Bull Case Gufic Biosciences Share Price Target: Rs 525

The bull case Gufic Biosciences share price target of Rs 525 materialises when FY27 earnings beat analyst estimates, Pharmaceutical Formulations and Biologics tailwinds accelerate beyond consensus, and FII flows return strongly to Indian equities. Under this scenario, Gufic Biosciences re-rates toward higher peer multiples, making Rs 525 achievable within FY28. The current gap between CMP Rs 360.4 and Rs 525 represents approximately 45 percent potential upside.

Bear Case Gufic Biosciences Share Price Target: Rs 290

The bear case Gufic Biosciences share price target of Rs 290 materialises if FY27 earnings disappoint, management guides below expectations, or sustained FII outflows depress the broader mid-cap market. Under this scenario, the stock risks testing the 52 week low support near Rs 250, and investors should reassess the investment thesis before adding more capital.

Key Risks That Could Derail the Gufic Biosciences 2026 Price Objective

Global Macro and US Tariff Headwinds

The prolonged tariff tension triggered by the US reciprocal tariff announcement in 2026 has reduced FII risk appetite for Indian equities. A global demand slowdown or escalation in trade tensions remains the most prominent macro risk to the Gufic Biosciences share price target of Rs 430 and could push the stock toward the bear case of Rs 290.

FY27 Earnings Miss and Guidance Risk

Any FY27 earnings miss or downward guidance revision by Gufic Biosciences’s management would compress valuation multiples. This is the most direct company-specific risk to the Rs 430 analyst price objective. Investors should monitor quarterly results and management commentary closely, especially any signals about demand environment, pricing power, or margin compression in the Pharmaceutical Formulations and Biologics segment.

Competitive Intensity Among Pharmaceutical Formulations and Biologics Peers

Intensifying competition from peers in specialty pharma like Piramal Pharma and Sun Pharma could compress Gufic Biosciences’s market share and pricing power over the medium term. This structural risk must be weighed when assessing how defensible the earnings trajectory that underpins the Rs 430 analyst target truly is, particularly as new entrants and imports from China disrupt established market structures.

Liquidity Risk and FII Selling Pressure

Sustained FII outflows from Indian equities can delay the re-rating process regardless of company-level operational improvement. For smaller market cap stocks, liquidity constraints can amplify drawdowns significantly. Investors should size positions carefully and maintain stop losses to protect capital if the broader market de-rating continues through FY27.

How to Invest in Gufic Biosciences: A Step-by-Step Approach

Check the Univest Screener for live data

Before considering any investment based on the Gufic Biosciences share price target of Rs 430, review the company’s Q4 FY26 results and FY27 guidance released in 2026. Focus on revenue growth, operating margin trends, debt levels, and management commentary on Pharmaceutical Formulations and Biologics sector demand and competition.

Open a Demat and trading account with a SEBI registered stockbroker to trade Gufic Biosciences (NSE: GUFICBIO) with regulatory protection. Complete KYC, and before executing any order, study the competitive landscape among peers in specialty pharma like Piramal Pharma and Sun Pharma to assess whether Gufic Biosciences’s competitive position justifies the Rs 430 valuation.

Plan your entry using technical and fundamental triggers. The 52 week low of Rs 250 acts as a key support reference. A confirmed FY27 earnings uptick combined with positive guidance would validate the entry case. Always set a pre-defined stop loss below the 52 week low to limit downside.

Maintain position sizing discipline. Restrict any single stock to 3 to 5 percent of your total equity portfolio. This is especially important in the Pharmaceutical Formulations and Biologics space where sectoral cycles, regulatory changes, and commodity price swings can amplify volatility beyond initial expectations.

Always consult a SEBI registered financial advisor before making investment decisions based on any analyst price target or market commentary. SEBI Registration No. INH000013776.

Download the Univest iOS App or the Univest Android App to track Gufic Biosciences’s live share price and receive daily stock recommendations from SEBI registered analysts.

FAQs on Gufic Biosciences Share Price Target 2026

What is the Gufic Biosciences share price target for 2026?

Ans. The Gufic Biosciences share price target 2026 is Rs 430, implying approximately 20 percent upside from CMP Rs 360.4. The bull case estimate is Rs 525 and the bear case is Rs 290.

What was the Gufic Biosciences share price target for 2025?

Ans. The 2025 price target for Gufic Biosciences was based on FY26 earnings projections. The current 2026 analyst consensus stands at Rs 430, reflecting FY27 growth potential from CMP Rs 360.4.

Is Gufic Biosciences a good investment at Rs 360.4?

Ans. At Rs 360.4, Gufic Biosciences offers potential upside toward Rs 430 if FY27 earnings recover as projected. Whether the stock is a good buy depends on individual risk appetite, investment horizon, and portfolio goals. Consult a SEBI registered financial advisor before investing.

What are the key risks to the Gufic Biosciences share price target 2026?

Ans. Key risks to the Gufic Biosciences share price target of Rs 430 include FY27 earnings miss, global tariff headwinds, sustained FII outflows, and competitive pressure in the Pharmaceutical Formulations and Biologics sector. Monitoring quarterly results closely is essential.

What is the 52 week high and low of Gufic Biosciences?

Ans. The 52 week high of Gufic Biosciences is Rs 591 and the 52 week low is Rs 250. At CMP Rs 360.4, the stock is trading below its 52 week high and offers upside potential toward the Rs 430 analyst price objective.

What are the main growth catalysts for Gufic Biosciences in 2026?

Ans. Primary growth catalysts for Gufic Biosciences in 2026 include FY27 PAT recovery, Pharmaceutical Formulations and Biologics sector tailwinds, RBI rate cuts reducing cost of capital, Union Budget 2026-27 policy support, and normalisation of FII flows into Indian equities.

How does Gufic Biosciences compare to its peers?

Ans. Gufic Biosciences operates in Pharmaceutical Formulations and Biologics alongside peers in specialty pharma like Piramal Pharma and Sun Pharma. At CMP Rs 360.4 with MCap Rs 3,244 crore, the company is positioned as a potential re-rating candidate toward the Gufic Biosciences share price target of Rs 430 on FY27 earnings delivery.

What is the Gufic Biosciences share price target for 2027?

Ans. The long-term Gufic Biosciences share price target for FY27 to FY28 is Rs 525 in the bull case, assuming continued earnings growth, sector re-rating, and sustained FII inflows. Consult a SEBI registered financial advisor for personalised guidance.